Topical Collection

Marine Compounds and Cancer

Message from the Collection Editors

This Topical Collection will cover the whole scope from agents with cancer-preventive activity, to novel and previously characterized compounds with anti-cancer activity, both in vitro and in vivo, and the latest status of clinical development from drug trials. Notably, compounds possessing pro-carcinogenic activity or mediating cancer cell survival are also within the scope of this Topical Collection. In addition, special focus will be placed on current shortfalls and possible strategies to overcome obstacles in the area of marine anti-cancer drug development.

Collection Editors

Dr. Friedemann Honecker

Tumor and Breast Center ZeTuP St. Gallen, Rorschacherstr. 150, 9006 St. Gallen. Switzerland

Dr. Sergey A. Dyshlovoy

1. Laboratory of Experimental Oncology, Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald-Tumorzentrum, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

2. Martini-Klinik, Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany



Marine Drugs

an Open Access Journal by MDPI

Impact Factor 4.9 CiteScore 9.6 Indexed in PubMed



mdpi.com/si/2496

Marine Drugs MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 marinedrugs@mdpi.com

mdpi.com/journal/ marinedrugs





an Open Access Journal by MDPI

Impact Factor 4.9 CiteScore 9.6 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

